Completed PHASE4 INTERVENTIONAL 2-arm NCT01310127

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery

Sponsor: Bausch & Lomb Incorporated

Conditions Inflammation Pseudophakia

Interventions Bromfenac Nepafenac

Updated 8 times since 2017 Last updated: Oct 8, 2020 Started: Nov 30, 2010 Primary completion: Apr 30, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Inflammation and Pseudophakia and is currently completed. Bausch & Lomb Incorporated leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Nov 2020 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE4
Jan 2018 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Jan 2018 [monthly]

Completed PHASE4

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch & Lomb Incorporated
Toyos Clinic

Data source: Toyos Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.